Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Duvelisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Secura Bio Presents Combination Data of COPIKTRA® at ASH 2024
    Secura Bio Presents Combination Data of COPIKTRA® at ASH 2024

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993617/0/en/New-Combination-Data-of-Secura-Bio-s-COPIKTRA-duvelisib-Presented-at-the-2024-American-Society-of-Hematology-Meeting.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Secura Bio's Copiktra Data in Relapsed T-cell Lymphoma at ASH 2024
    Secura Bio's Copiktra Data in Relapsed T-cell Lymphoma at ASH 2024

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993615/0/en/Secura-Bio-Presented-New-Data-from-its-Phase-2-PRIMO-Trial-of-Copiktra-Duvelisib-in-Relapsed-or-Refractory-Peripheral-T-cell-Lymphoma-and-Announced-Plans-for-its-Phase-3-TERZO-Tria.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Secura Bio to Present Copiktra® Data at ASH 2024
    Secura Bio to Present Copiktra® Data at ASH 2024

    06 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/06/2975561/0/en/Secura-Bio-Announces-Poster-Presentation-Highlighting-New-COPIKTRA-duvelisib-Data-for-the-Treatment-of-Patients-With-Peripheral-T-Cell-Lymphoma-and-Other-Advanced-Hematologic-Malig.html

    GLOBENEWSWIRE
    06 Nov 2024
    Share Share
    Secura Bio to keep offering blood cancer drug despite negative ODAC vote
    Secura Bio to keep offering blood cancer drug despite negative ODAC vote

    23 Mar 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/secura-bio-to-keep-offering-blood-cancer-drug-despite-negative-odac-vote-os-questions/

    Zachary Brennan ENDPTS
    23 Mar 2023
    Share Share
    Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib
    Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib

    09 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/secura-bio-inc-receives-orphan-drug-designation-in-europe-for-duvelisib-for-the-treatment-of-patients-with-peripheral-t-cell-lymphoma-301713925.html

    PR NEWSWIRE
    09 Jan 2023
    Share Share
    FDA threatens to clamp down on another PI3K blood cancer drug—a full approval
    FDA threatens to clamp down on another PI3K blood cancer drug—a full approval

    23 Sep 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/fda-threatens-clamp-down-another-pi3k-blood-cancer-drug-time-full-approval

    Angus Liu FIERCEPHARMA
    23 Sep 2022
    Share Share